MARÍA DEL PILAR
MARTÍNEZ SÁNCHEZ
Profesora asociada de Ciencias de la Salud
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Puerta de Hierro (17)
2024
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology
2023
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
2022
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
Therapeutic Advances in Gastroenterology, Vol. 14
2020
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
2018
-
Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279
2017
-
Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial
Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
-
Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease
Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800
2012
-
Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases
Journal of Crohn's and Colitis, Vol. 6, Núm. 5, pp. 518-523
2011
-
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
Alimentary Pharmacology and Therapeutics, Vol. 33, Núm. 3, pp. 340-348
-
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience
Gastroenterologia y Hepatologia, Vol. 34, Núm. 7, pp. 443-448
2008
-
Open-label infliximab therapy in Crohn's disease: A long-term multicenter study of efficacy, safety and predictors of response
Gastroenterologia y Hepatologia, Vol. 31, Núm. 7, pp. 421-426